Editorial: Imaging technology in oncology pharmacological research, volume II

Qi Zeng, Xu Cao, Jinchao Feng, Hong Shan, Xueli ChenFrontiers in Pharmacology 2022 · DOI · OpenAlex

TL;DR

This editorial summarizes a collection of five research articles that demonstrate how advanced imaging—ranging from high-brightness fluorescent probes to AI-driven radiomics—is transforming oncology pharmacology. By bridging the gap between molecular drug screening and clinical diagnostics, these technologies enable more precise drug evaluation and non-invasive "virtual biopsies" for personalized cancer treatment.

What Problem Does This Paper Address?

The development of effective anti-cancer drugs is a high-stakes, complex process that requires precise monitoring at every stage, from initial cellular screening to clinical application. Traditionally, researchers have struggled with two main hurdles:

  1. Screening Efficiency: Identifying how candidate compounds interact with signaling pathways (like GPCR-cAMP) requires highly sensitive tools that can provide clear signals in high-throughput environments.
  2. Non-Invasive Diagnostics: In the clinic, determining a patient’s specific genetic mutation (e.g., EGFR or KRAS status in lung cancer) is crucial for choosing the right therapy. However, physical biopsies are invasive and sometimes risky.

This editorial highlights how modern imaging technology acts as a "powerful tool" to solve these problems by providing detailed morphological and functional information across both in vitro (laboratory) and in vivo (living organism) settings.

Methods

The editorial reviews five distinct methodological approaches across the featured studies:

  • Genetically Encoded Sensors: One study describes G-Flamp2, an improved fluorescent probe designed for high-content screening (HCS). It offers higher brightness and a larger dynamic range than its predecessors, allowing researchers to track cAMP signaling pathways more effectively.
  • High-Throughput Virtual Screening: Researchers used structural-based screening to identify terphenyllin (a marine-derived product) as a potential STAT3 inhibitor, subsequently validating its efficacy through fluorescence imaging in mouse models.
  • Radiomics and Deep Learning: Three studies focused on "Radiomics"—the extraction of massive amounts of quantitative data from standard medical images (CT and PET/CT). These studies employed:
  • Hybrid Models: Combining clinical characteristics (like smoking history) with deep learning features.
  • Ensemble Modeling: Using over 1,400 radiomics features to improve prediction accuracy.
  • Multimodality Integration: Combining PET/CT data with known genetic markers to predict secondary mutations.

Datasets

The clinical studies highlighted in this editorial utilized specific patient cohorts for training and validation:

  • Huang et al.: PET/CT images from 194 patients with non-small cell lung cancer (NSCLC).
  • Feng et al.: CT images from 168 NSCLC patients, focusing on 1,409 extracted radiomics features.
  • Wang et al.: $^{18}$F-FDG PET/CT multimodality data from 258 NSCLC patients.
  • Note: The laboratory-based studies (Liu et al. and Yu et al.) utilized cell lines and orthotopic mouse models, though specific dataset names were not listed in the editorial summary.

Key Insights and Ideas

  • The "Virtual Biopsy": The most significant takeaway is the shift toward using imaging as a non-invasive alternative to traditional biopsies. By analyzing the "texture" and "features" of a tumor on a scan, AI can predict genetic mutations that previously required tissue samples.
  • Brightness is Key for Discovery: In drug screening, the transition from G-Flamp1 to G-Flamp2 shows that incremental improvements in probe brightness and dynamic range ($\Delta F/F_0$) can significantly enhance the reliability of high-content screening for new drugs.
  • Synergy of Human and Machine Data: The success of the "hybrid model" (combining smoking history with AI features) suggests that clinical context remains vital; AI performs best when augmented with traditional medical knowledge rather than operating in a vacuum.

Key Results

  • Improved Mutation Prediction: The ensemble and hybrid models demonstrated superior diagnostic performance in predicting EGFR mutation status, which is a critical factor in deciding which targeted therapies to use for lung cancer patients.
  • Reduced Error Rates: One ensemble model specifically succeeded in significantly reducing false-positive rates in genetic predictions compared to standard imaging analysis.
  • Discovery of Terphenyllin: Fluorescence imaging confirmed that terphenyllin effectively inhibits the growth and metastasis of gastric cancer by targeting the STAT3 signaling pathway without significant systemic toxicity.

Limitations and Future Work

While the editorial celebrates these advancements, it implicitly points toward several challenges:

  • Generalizability: The radiomics models were developed on relatively small cohorts (168–258 patients). Future work will likely require larger, multi-center datasets to ensure these AI models work across different populations and imaging hardware.
  • Clinical Integration: While these "virtual biopsies" are promising, the editorial notes they currently serve as "assistant information." Moving from an experimental tool to a standard clinical diagnostic will require further validation.
  • Volume III and Beyond: The authors conclude that these articles continue to embody the value of imaging in both basic and clinical research, suggesting that the field is still in a high-growth phase with more integrated "multimodality" approaches on the horizon.

Summary updated

Abstract

Nowadays, imaging technology is well acknowledged as an important tool for drug development. Imaging could provide more detail and precise morphology or functionality information in gene expression, metabolism of various substances, cancer detection, drug development, as well as other fields. Similar to the previous Volume I, the research topic "Imaging Technology in Oncology Pharmacological Research, Volume II" provides an academic platform to discuss the latest oncology pharmacological works based on imaging technology.
BibTeX
@inproceedings{zeng2022editorial,
  author = {Qi Zeng and Xu Cao and Jinchao Feng and Hong Shan and Xueli Chen},
  title = {{Editorial: Imaging technology in oncology pharmacological research, volume II}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.977434},
}

Loading related content...

Figure